Akums reports Q1 FY26 PAT at Rs. 65 Cr
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
Upgrades 2025 full-year CDMO sales and margin outlook
Subscribe To Our Newsletter & Stay Updated